Grifols S.A. (GRFS)
GRFS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2024-12-31, https://www.sec.gov/Archives/edgar/data/1438569/000110465925034245/0001104659-25-034245-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2024-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | GRFS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Spain |
| IPO year | Not reported by the screener |
| SEC CIK | 0001438569 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $8.1B |
| Net income | $175.7M |
| Operating income | Not in SEC XBRL data |
| Net margin | 2.2% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 28.1× |
| P/S (computed) | 0.6× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2015-04-23 |
| Latest annual report FORM 20-F | 20-F | 2026-04-17 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-07-30 |
Source: SEC EDGAR submissions feed, 461 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.5% |
| 1 month | -1.7% |
| 3 months | -1.3% |
| Year to date | -22.6% |
| 1 year | -23.4% |
| From 52-week high | -25.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TVTX | Travere Therapeutics Inc. | $51.80 | -0.42% | $4.9B |
| COGT | Cogent Biosciences Inc. | $28.09 | -5.67% | $4.9B |
| PTCT | PTC Therapeutics Inc. | $59.92 | -4.77% | $5.0B |
| MANE | Veradermics Incorporated | $116.26 | -5.02% | $4.9B |
| ERAS | Erasca Inc. | $14.78 | -4.40% | $5.2B |
| MIRM | Mirum Pharmaceuticals Inc. | $79.62 | -7.48% | $5.2B |
| DNTH | Dianthus Therapeutics Inc. | $77.58 | -4.89% | $4.3B |
| INDV | Indivior Pharmaceuticals Inc. | $35.42 | -1.77% | $4.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier